MX368721B - Moduladores de ror gamma (rory). - Google Patents
Moduladores de ror gamma (rory).Info
- Publication number
- MX368721B MX368721B MX2016007275A MX2016007275A MX368721B MX 368721 B MX368721 B MX 368721B MX 2016007275 A MX2016007275 A MX 2016007275A MX 2016007275 A MX2016007275 A MX 2016007275A MX 368721 B MX368721 B MX 368721B
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- cycloalkylc
- groups optionally
- cycloalkyl
- optionally substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- -1 hydroxy, methoxy Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195813 | 2013-12-05 | ||
| EP14183274 | 2014-09-02 | ||
| PCT/EP2014/076390 WO2015082533A1 (en) | 2013-12-05 | 2014-12-03 | Ror gamma (rory) modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007275A MX2016007275A (es) | 2017-01-05 |
| MX368721B true MX368721B (es) | 2019-10-14 |
Family
ID=52021176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007275A MX368721B (es) | 2013-12-05 | 2014-12-03 | Moduladores de ror gamma (rory). |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9738600B2 (enExample) |
| EP (1) | EP3077372B8 (enExample) |
| JP (1) | JP6461960B2 (enExample) |
| KR (1) | KR102251128B1 (enExample) |
| CN (1) | CN105980353B (enExample) |
| AU (1) | AU2014359324B2 (enExample) |
| CA (1) | CA2932483C (enExample) |
| CL (1) | CL2016001364A1 (enExample) |
| CR (1) | CR20160303A (enExample) |
| DK (1) | DK3077372T3 (enExample) |
| DO (1) | DOP2016000125A (enExample) |
| EA (1) | EA030393B1 (enExample) |
| ES (1) | ES2722409T3 (enExample) |
| HR (1) | HRP20190483T1 (enExample) |
| HU (1) | HUE043258T2 (enExample) |
| IL (1) | IL246018B (enExample) |
| LT (1) | LT3077372T (enExample) |
| MX (1) | MX368721B (enExample) |
| MY (1) | MY179106A (enExample) |
| PE (1) | PE20160891A1 (enExample) |
| PH (1) | PH12016501066A1 (enExample) |
| PL (1) | PL3077372T3 (enExample) |
| PT (1) | PT3077372T (enExample) |
| RS (1) | RS58650B1 (enExample) |
| SI (1) | SI3077372T1 (enExample) |
| TN (1) | TN2016000224A1 (enExample) |
| UA (1) | UA117941C2 (enExample) |
| WO (1) | WO2015082533A1 (enExample) |
| ZA (1) | ZA201604043B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3122721A4 (en) * | 2014-03-27 | 2018-01-10 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| MX2016013518A (es) * | 2014-04-16 | 2017-01-23 | Glenmark Pharmaceuticals Sa | Compuestos de aril y heteroaril eter como moduladores de ror gamma. |
| JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
| RS58250B1 (sr) | 2014-10-30 | 2019-03-29 | Janssen Pharmaceutica Nv | Tiazoli kao modulatori roryt |
| SMT201900706T1 (it) | 2014-10-30 | 2020-01-14 | Janssen Pharmaceutica Nv | Tiazoli sostituiti con ammide come modulatori di rorgammat |
| CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| MX394388B (es) | 2015-05-15 | 2025-03-21 | Aurigene Discovery Tech Ltd | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma |
| WO2016193894A1 (en) * | 2015-05-29 | 2016-12-08 | Glenmark Pharmaceuticals S.A. | Treatment of respiratory disorders using ror- gamma inhibitors |
| EP3101005A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101008A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| WO2017010399A1 (ja) * | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| CN109071516B (zh) | 2015-12-15 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | 新颖的化合物 |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| TW201815388A (zh) * | 2016-07-14 | 2018-05-01 | 印度商卡迪拉保健有限公司 | 作為ＲＯＲγ調節劑之新穎化合物 |
| BR112019000603A2 (pt) | 2016-07-14 | 2019-04-30 | Cadila Healthcare Limited | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto |
| AR110481A1 (es) * | 2016-12-05 | 2019-04-03 | Lead Pharma Holding Bv | MODULADORES DE ROR g (RORg) |
| WO2018116285A1 (en) * | 2016-12-23 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Substituted morpholine derivatives as ror gamma modulators |
| WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
| JP2021527660A (ja) | 2018-06-18 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール |
| ES2928246T3 (es) | 2018-06-18 | 2022-11-16 | Janssen Pharmaceutica Nv | 6-aminopiridin-3-il pirazoles como moduladores de RORyt |
| CN112292373A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
| EP3921038A1 (en) | 2019-02-06 | 2021-12-15 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
| WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
| CN112759541B (zh) * | 2019-10-21 | 2023-03-17 | 复旦大学 | 类吲哚衍生物及其用途 |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| CN113072521B (zh) * | 2020-01-06 | 2024-04-05 | 广东东阳光药业股份有限公司 | RORγt抑制剂及其在药物中的应用 |
| CN114075139B (zh) * | 2020-08-14 | 2025-09-26 | 广东东阳光药业股份有限公司 | 五元杂芳环类化合物及其在药物中的应用 |
| WO2025157313A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海医药集团股份有限公司 | 一种乙磺酰苯基乙酰胺类化合物的晶型、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| AU2013331493A1 (en) * | 2012-10-16 | 2015-04-09 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORyt |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| RU2015141592A (ru) * | 2013-03-15 | 2017-04-21 | Ф. Хоффманн-Ля Рош Аг | АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
-
2014
- 2014-12-03 UA UAA201607189A patent/UA117941C2/uk unknown
- 2014-12-03 CN CN201480074695.6A patent/CN105980353B/zh not_active Expired - Fee Related
- 2014-12-03 KR KR1020167017849A patent/KR102251128B1/ko active Active
- 2014-12-03 MY MYPI2016702008A patent/MY179106A/en unknown
- 2014-12-03 AU AU2014359324A patent/AU2014359324B2/en not_active Ceased
- 2014-12-03 EP EP14809794.2A patent/EP3077372B8/en active Active
- 2014-12-03 CR CR20160303A patent/CR20160303A/es unknown
- 2014-12-03 EA EA201691173A patent/EA030393B1/ru not_active IP Right Cessation
- 2014-12-03 PE PE2016000733A patent/PE20160891A1/es unknown
- 2014-12-03 LT LTEP14809794.2T patent/LT3077372T/lt unknown
- 2014-12-03 MX MX2016007275A patent/MX368721B/es active IP Right Grant
- 2014-12-03 ES ES14809794T patent/ES2722409T3/es active Active
- 2014-12-03 HR HRP20190483TT patent/HRP20190483T1/hr unknown
- 2014-12-03 HU HUE14809794A patent/HUE043258T2/hu unknown
- 2014-12-03 US US15/102,098 patent/US9738600B2/en not_active Expired - Fee Related
- 2014-12-03 PL PL14809794T patent/PL3077372T3/pl unknown
- 2014-12-03 TN TN2016000224A patent/TN2016000224A1/en unknown
- 2014-12-03 RS RS20190494A patent/RS58650B1/sr unknown
- 2014-12-03 JP JP2016536162A patent/JP6461960B2/ja not_active Expired - Fee Related
- 2014-12-03 WO PCT/EP2014/076390 patent/WO2015082533A1/en not_active Ceased
- 2014-12-03 CA CA2932483A patent/CA2932483C/en active Active
- 2014-12-03 DK DK14809794.2T patent/DK3077372T3/en active
- 2014-12-03 PT PT14809794T patent/PT3077372T/pt unknown
- 2014-12-03 SI SI201431174T patent/SI3077372T1/sl unknown
-
2016
- 2016-06-03 CL CL2016001364A patent/CL2016001364A1/es unknown
- 2016-06-03 PH PH12016501066A patent/PH12016501066A1/en unknown
- 2016-06-03 DO DO2016000125A patent/DOP2016000125A/es unknown
- 2016-06-05 IL IL246018A patent/IL246018B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04043A patent/ZA201604043B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501066A1 (en) | ROR GAMMA (ROYy) MODULATORS | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| BR112015004113A2 (pt) | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| CY1120682T1 (el) | Ενωσεις για την προστασια κυτταρων | |
| NZ727792A (en) | Therapeutic compounds | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PH12015502192A1 (en) | Novel compounds | |
| IN2014MN02459A (enExample) | ||
| MX377581B (es) | Compuestos antihelmínticos y composiciones y método de uso de los mismos. | |
| EA201590539A1 (ru) | C17-гетероарильные производные олеаноловой кислоты и способы их применения | |
| MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
| PH12017500048A1 (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| BR112017026231A2 (pt) | moduladores de ror gama (rory) | |
| EA201590561A1 (ru) | Пролекарства аминохиназолинового ингибитора киназы | |
| MX348084B (es) | Compuestos de cetolido. | |
| CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος | |
| MX372772B (es) | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| MY180006A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| PH12013501856A1 (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these | |
| MX369470B (es) | Medios y método para el tratamiento de tumores sólidos. | |
| SA519400868B1 (ar) | معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: LEAD PHARMA HOLDING B.V. |
|
| FG | Grant or registration |